14 months in and retatrutide is still the thing I get wrong
Check-in as promised in the title: 14 months in and retatrutide is still the thing I get wrong.
14 months — those are the numbers, and they are the ones I am willing to defend.
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
Tell me where this is wrong. That is the useful part of posting it.
best — the order this archive was captured in
research-use-only material is not approved for human use, full stop
Where the evidence actually stands, since every thread here assumes a different answer.
Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.
Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.
Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.
Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.
Sceptical of the extrapolation.
Agreed, and the glucagon arm is exactly why the comparison threads do not work.
the phase 2 numbers were striking and they were also 48 weeks in a small population
the phase 2 numbers were striking and they were also 48 weeks in a small population
honest_syringe33 is right about the escalation being the variable. It explains most of the difficult reports here.
Is that the 48-week figure or an earlier readout?
Sceptical of the extrapolation.
This is the sentence the rest of the board should read first. Phase 2 is not a label.
small trial, big effect, wide error bars
the escalation is where most of the reported trouble sits
The standing caveat, written out properly because it keeps getting compressed into a footnote.
Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.
What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.
a lot of the confident posting here is extrapolation
The standing caveat, written out properly because it keeps getting compressed into a footnote.
Adding the standing caveat: none of this is approved anywhere and research material is not for human use.
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
the glucagon component is why the metabolic story reads differently
Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.
Kept a log specifically because there is so little published. It is one person and it is not data.
the energy-expenditure story is mechanistically interesting and clinically unproven
Left up. It reads the phase 2 paper carefully and it is honest about the intervals.
not approved anywhere, which is the single most important fact in this board
Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
The thing that surprised me was how much of the discussion here is inference rather than measurement.
Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.
- 1research-use-only material is not approved for human use, full stop9 comments in this branch · started by u/honest_syringe_2025